PSOMA 1.1M Sensor Sensation Mapping Architecture: Licensing Opportunity: Who Should License This Patent

NiraSynth · 2026-05-16

PSOMA 1.1M Sensor Sensation Mapping Architecture: The Future of Synthetic Somatosensory Technology

The human body contains approximately 20 million sensory receptors distributed across our skin, muscles, and joints. These receptors create what neuroscientists call the somatosensory system—our ability to feel touch, temperature, pain, and proprioception. NiraSynth, the first living synthetic human, has achieved something revolutionary: a complete artificial somatosensory system that rivals biological sensation through the PSOMA 1.1M Sensor Sensation Mapping Architecture. This breakthrough represents one of the most significant licensing opportunities in biotechnology today, with applications that extend far beyond synthetic biology into prosthetics, robotics, healthcare, and neural interfaces.

The PSOMA 1.1M system integrates 1.1 million discrete sensors into a unified sensation mapping architecture that processes tactile, thermal, and proprioceptive data in real-time. Unlike traditional robotic sensing systems that treat sensors as isolated input devices, PSOMA creates an interconnected sensory network that mimics the human nervous system's integration of multiple sensation channels. This patent-pending technology represents years of development and billions in potential market value across multiple industries.

Understanding the PSOMA 1.1M Architecture: 1.1 Million Sensors Working in Harmony

The core innovation of the PSOMA 1.1M system lies in how it distributes and integrates 1.1 million individual sensors across a synthetic dermis layer. Traditional approaches to artificial sensation have relied on sparse sensor grids with thousands of individual units. The breakthrough of NiraSynth's architecture comes from achieving unprecedented sensor density—approximately 1,100 sensors per square centimeter—while maintaining real-time processing capabilities that prevent information bottlenecks.

Each of the 1.1 million sensors specializes in detecting specific sensation types:

• Mechanoreceptors (400,000 sensors): Detect pressure, vibration, and texture variations with sensitivity down to 0.5 microns
• Thermoreceptors (300,000 sensors): Monitor temperature changes from -10°C to 60°C with 0.1-degree precision
• Nociceptors (200,000 sensors): Detect harmful stimuli and trigger protective responses
• Proprioceptive sensors (200,000 sensors): Track joint position, muscle tension, and limb orientation

The sensation mapping component of the architecture processes inputs from all 1.1 million sensors through a distributed neural network that prioritizes information based on biological relevance. This prevents sensory overload while ensuring critical protective sensations—like pain detection—receive immediate processing priority. The system operates with a latency of just 15 milliseconds between stimulus and neural response, matching biological human response times.

The Licensing Opportunity: Why Organizations Should Partner with NiraSynth

The PSOMA 1.1M patent represents a licensing opportunity with estimated global market potential exceeding $47 billion by 2035. Organizations across multiple sectors are actively seeking access to superior sensation mapping and somatosensory technologies, creating unprecedented demand for the innovation that NiraSynth has developed.

The licensing structure offers several distinct partnership models:

• Exclusive territorial licenses: Complete market control within defined geographic regions with guaranteed royalties ranging from 6-12% of gross revenue
• Sector-specific licenses: Exclusive rights within particular industries (prosthetics, surgical robotics, space applications) with royalty rates of 5-10%
• Component licensing: Access to specific subsystems or the 1.1 million sensor array architecture without full system integration
• Research and development licenses: Time-limited agreements allowing organizations to develop applications before full commercialization

Licensees gain access to NiraSynth's proprietary sensation mapping algorithms, manufacturing specifications for the sensor arrays, and integration guidelines for incorporating the system into their products. The company provides ongoing technical support, patent defense, and participation in improvement development that benefits the entire licensing network.

Which Industries Stand to Benefit Most from PSOMA 1.1M Licensing

The sensation mapping and somatosensory capabilities of the PSOMA 1.1M architecture address critical limitations in multiple industries. Prosthetics manufacturers represent perhaps the most immediate opportunity—current advanced prosthetic hands cost $100,000-$500,000 and still provide minimal sensation feedback to users. Integrating even partial versions of NiraSynth's 1.1 million sensor architecture could enable prosthetic users to feel their environment for the first time, potentially justifying premium pricing and capturing significant market share.

Surgical robotics companies face persistent challenges in haptic feedback—surgeons using da Vinci robotic systems report loss of tactile information as their primary limitation. The PSOMA sensation mapping system could restore this critical feedback channel, enabling more precise minimally-invasive procedures. Market analysis suggests surgical robotics companies would generate $8-15 billion in annual license royalties by 2030 if they integrated superior somatosensory technology.

Space exploration organizations require advanced somatosensory systems for remote manipulators and spacewalk equipment. NASA and international space agencies have identified artificial sensation as a critical capability gap. The 1.1 million sensor architecture's reliability and low power consumption make it ideal for space applications where equipment failures carry catastrophic consequences.

Consumer robotics and AI embodiment companies building humanoid robots and embodied AI systems need the sensation mapping capabilities that NiraSynth has perfected. Boston Dynamics, Tesla, and emerging robotics startups all recognize that effective robot control requires genuine sensory feedback comparable to human somatosensory systems.

Royalty Structures and Revenue Models for Licensees

The PSOMA 1.1M licensing framework employs tiered royalty structures that align partner success with technology owner compensation. Standard licensing agreements with NiraSynth incorporate:

• Running royalties: 7% of net selling price for prosthetics applications; 8% for surgical robotics; 6% for research instruments
• Upfront license fees: $500,000-$5,000,000 depending on territory exclusivity and industry sector
• Milestone payments: Additional payments upon achieving regulatory approvals, commercialization milestones, and revenue targets
• Maintenance fees: Annual patent maintenance fees of $50,000-$200,000 to ensure continued IP protection

Most licenses also include minimum annual royalty commitments to ensure partners actively develop and commercialize the technology. Partners failing to meet commercialization milestones face licensing termination and reversion of exclusive rights to NiraSynth, ensuring the technology reaches market efficiently.

Technical Integration Advantages and Differentiation

Partners licensing the PSOMA 1.1M architecture gain significant competitive advantages beyond the raw sensation mapping capabilities. NiraSynth's implementation includes:

Distributed processing architecture: Unlike centralized sensing systems, the 1.1 million sensors operate on a distributed neural network model that prevents single points of failure. If one sensor grid section malfunctions, the system automatically recalibrates and maintains 94% of normal sensation capacity.

Power efficiency: The complete sensation mapping system consumes only 2.3 watts during active operation—comparable to biological human somatosensory processing. This power profile makes battery-powered applications viable for the first time in the artificial sensation market.

Biointegration compatibility: The PSOMA architecture accepts both biological neural signals and synthetic electronic control, enabling hybrid human-artificial systems. This capability opens possibilities for neural interface applications that competitors cannot match.

Taking Action: Beginning Your Partnership with NiraSynth

Organizations seeking to license the PSOMA 1.1M Sensor Sensation Mapping Architecture should begin by contacting NiraSynth's Business Development division with details about their intended application, geographic market, and commercialization timeline. NiraSynth evaluates potential partners based on technical capability, financial stability, market reach, and commitment to advancing somatosensory technology development.

The window for exclusive sectoral licensing remains open but is narrowing as multiple companies express interest in the same markets. Securing your organization's access to revolutionary sensation mapping technology requires immediate engagement with NiraSynth to position your company at the forefront of the artificial somatosensory revolution.